One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Lawrence Corey, Peter B. Gilbert, Michal Juraska, David C. Montefiori, Lynn Morris, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mavis Mgodi, Allan C. deCamp, Erika Rudnicki and 35 more
BACKGROUNDWhether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODSWe enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial.Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total.HIV-1 testing was performed every 4 weeks.The VRC01 80% inhibitory concentration (IC 80 ) of acquired isolates was measured with the TZM-bl assay. RESULTSAdverse events were similar in number and severity among the treatment groups within each trial.Among the 2699 participants in HVTN 704/HPTN 085, HIV-1 infection occurred in 32 in the low-dose group, 28 in the high-dose group, and 38 in the placebo group.Among the 1924 participants in HVTN 703/HPTN 081, infection occurred in 28 in the low-dose group, 19 in the high-dose group, and 29 in the placebo group.The incidence of HIV-1 infection per 100 person-years in HVTN 704/ HPTN 085 was 2.35 in the pooled VRC01 groups and 2.98 in the placebo group (estimated prevention efficacy, 26.6%; 95% confidence interval [CI], -11.7 to 51.8; P = 0.15), and the incidence per 100 person-years in HVTN 703/HPTN 081 was 2.49 in the pooled VRC01 groups and 3.10 in the placebo group (estimated prevention efficacy, 8.8%; 95% CI, -45.1 to 42.6; P = 0.70).In prespecified analyses pooling data across the trials, the incidence of infection with VRC01-sensitive isolates (IC 80 <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9).The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONSVRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.(Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials .govnumbers, NCT02716675 and NCT02568215.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., Huang, Y., Gonzáles, P., Cabello, R. L., Orrell, C., Lama, J. R., Laher, F., Lazarus, E. M., Sánchez, J., Frank, I., … Cohen, M. S. (2021). Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 384(11), 1003–1014. https://doi.org/10.1056/nejmoa2031738
Corey, Lawrence, et al. "Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition." New England Journal of Medicine, vol. 384, no. 11, 2021, pp. 1003–1014, https://doi.org/10.1056/nejmoa2031738.
Corey, Lawrence, Peter B. Gilbert, Michal Juraska, David C. Montefiori, Lynn Morris, Shelly Karuna, Srilatha Edupuganti, et al. "Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition." New England Journal of Medicine 384, no. 11 (2021): 1003–1014. https://doi.org/10.1056/nejmoa2031738.
Corey L., Gilbert P. B., Juraska M. [и др.] Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition // New England Journal of Medicine. — 2021. — Vol. 384, № 11. — P. 1003–1014. — URL: https://doi.org/10.1056/nejmoa2031738
@article{corey2021randomized,
title = {{Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition}},
author = {Lawrence Corey and Peter B. Gilbert and Michal Juraska and David C. Montefiori and Lynn Morris and Shelly Karuna and Srilatha Edupuganti and Nyaradzo Mavis Mgodi and Allan C. deCamp and Erika Rudnicki and Yunda Huang and Pedro Gonzáles and Robinson L. Cabello and Catherine Orrell and Javier R. Lama and Fatima Laher and Erica Maxine Lazarus and Jorge Sánchez and Ian Frank and Juan Hinojosa and Magdalena E. Sobieszczyk and KYLE E. MARSHALL and Pamela Grace Mukwekwerere and Joseph M. Makhema and Lindsey Robert Baden and James I. Mullins and Carolyn E. Williamson and John Hural and M. Juliana McElrath and Carter Bentley and Simbarashe G. Takuva and Margarita M. Gomez Lorenzo and David Burns and Nicole Espy and April Kaur Randhawa and Nidhi K. Kochar and Estelle Piwowar‐Manning and Deborah J Donnell and Nirupama Sista and P. Andrew and James G. Kublin and Glenda Gray and Julie E. Ledgerwood and John R. Mascola and Myron S. Cohen},
journal = {New England Journal of Medicine},
year = {2021},
volume = {384},
number = {11},
pages = {1003--1014},
doi = {10.1056/nejmoa2031738},
url = {https://doi.org/10.1056/nejmoa2031738}
}TY - JOUR AU - Corey, Lawrence AU - Gilbert, Peter B. AU - Juraska, Michal AU - Montefiori, David C. AU - Morris, Lynn AU - Karuna, Shelly AU - Edupuganti, Srilatha AU - Mgodi, Nyaradzo Mavis AU - deCamp, Allan C. AU - Rudnicki, Erika AU - Huang, Yunda AU - Gonzáles, Pedro AU - Cabello, Robinson L. AU - Orrell, Catherine AU - Lama, Javier R. AU - Laher, Fatima AU - Lazarus, Erica Maxine AU - Sánchez, Jorge AU - Frank, Ian AU - Hinojosa, Juan AU - Sobieszczyk, Magdalena E. AU - MARSHALL, KYLE E. AU - Mukwekwerere, Pamela Grace AU - Makhema, Joseph M. AU - Baden, Lindsey Robert AU - Mullins, James I. AU - Williamson, Carolyn E. AU - Hural, John AU - McElrath, M. Juliana AU - Bentley, Carter AU - Takuva, Simbarashe G. AU - Lorenzo, Margarita M. Gomez AU - Burns, David AU - Espy, Nicole AU - Randhawa, April Kaur AU - Kochar, Nidhi K. AU - Piwowar‐Manning, Estelle AU - Donnell, Deborah J AU - Sista, Nirupama AU - Andrew, P. AU - Kublin, James G. AU - Gray, Glenda AU - Ledgerwood, Julie E. AU - Mascola, John R. AU - Cohen, Myron S. TI - Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition JO - New England Journal of Medicine VL - 384 IS - 11 SP - 1003 EP - 1014 PY - 2021 DA - 2021/03/17 DO - 10.1056/nejmoa2031738 UR - https://doi.org/10.1056/nejmoa2031738 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.